Evofem Biosciences, Inc.
EVFM- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001618835
No open-market purchases or sales by Evofem Biosciences, Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Q2 2022 vs. Q1 2022
How the institutions holding Evofem Biosciences, Inc. changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Q2 2022 | Change |
|---|---|---|---|
| Holders | 68 | 44 | −24 |
| Shares | 19.7M | 7.61M | −12.1M (−61.4%) |
| Value | $6.66M | $11.6M | +$4.90M (+73.6%) |
New holders (10)
Institutions that held Evofem Biosciences, Inc. at the end of Q2 2022 but not at the end of Q1 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Baker Bros. Advisors LP | 2,583,616 | $2.92M | 0.02% |
| Alyeska Investment Group, L.P. | 1,950,607 | $2.20M | 0.03% |
| National Asset Management, Inc. | 42,108 | $48.0K | 0.00% |
| Schonfeld Strategic Advisors LLC | 28,100 | $32.0K | 0.00% |
| Sassicaia Capital Advisers LLC | 27,000 | $31.0K | 0.19% |
| Mercer Global Advisors Inc | 15,001 | $17.0K | 0.00% |
| Creative Planning | 10,356 | $12.0K | 0.00% |
| HCR Wealth Advisors | 10,011 | $11.0K | 0.00% |
| Shay Capital LLC | 2,500 | $3.00K | 0.00% |
| Federation des caisses Desjardins du Quebec | 31 | $35 | 0.00% |
Sold out (34)
Institutions that held Evofem Biosciences, Inc. at the end of Q1 2022 and filed for Q2 2022 without it.